Hemoperfusion for Theophylline Poisoning: Case Report

Volume: 40 Number: 2 June 1, 2014
EN TR

Hemoperfusion for Theophylline Poisoning: Case Report

Abstract

Theophylline is a methylxanthine derivative which is used in the treatment of bronchospastic pulmonary diseases. The therapeutic range of theophylline is very narrow. It carries a risk for intoxication when the blood level is over 15μg/mL. Serious theophylline poisoning should be treated in intensive care conditions as it may cause fatal consequences. In these cases, gastric lavage, active charcoal administration through a nasogastric tube and symptomatic treatments can be applied. If these treatments are unsuccessful, extracorporeal methods like hemodialysis or charcoal hemoperfusion can be applied. We present two cases which were unresponsive to method of classic treatment and treated with hemoperfusion after theophylline intoxication. The first case presented with nausea, vomiting, and tremor refractory to treatment. The second case experienced extensive episodes of hypotension, atrial fibrillation, tonic clonic seizures and finally cardio pulmonary arrest. Cardiopul-monary ressuciation was successful. Both cases were successfully discharged from the intensive care unit after hemoperfusion therapy. In conclusion, hemoperfusion with active charcoal filters is a successful method for reducing serum theophylline concentration in patients unresponsive to classic supportive treatment.

Keywords

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Nermin Kelebek Girgin This is me

İsa Uran This is me

Bülent Gül This is me

Remzi İşçimen This is me

Ferda Kahveci This is me

Publication Date

June 1, 2014

Submission Date

June 1, 2014

Acceptance Date

-

Published in Issue

Year 2014 Volume: 40 Number: 2

APA
Çalışkan, G., Girgin, N. K., Uran, İ., Gül, B., İşçimen, R., & Kahveci, F. (2014). Hemoperfusion for Theophylline Poisoning: Case Report. Journal of Uludağ University Medical Faculty, 40(2), 89-93. https://izlik.org/JA98RB72ZA
AMA
1.Çalışkan G, Girgin NK, Uran İ, Gül B, İşçimen R, Kahveci F. Hemoperfusion for Theophylline Poisoning: Case Report. Journal of Uludağ University Medical Faculty. 2014;40(2):89-93. https://izlik.org/JA98RB72ZA
Chicago
Çalışkan, Gülbahar, Nermin Kelebek Girgin, İsa Uran, Bülent Gül, Remzi İşçimen, and Ferda Kahveci. 2014. “Hemoperfusion for Theophylline Poisoning: Case Report”. Journal of Uludağ University Medical Faculty 40 (2): 89-93. https://izlik.org/JA98RB72ZA.
EndNote
Çalışkan G, Girgin NK, Uran İ, Gül B, İşçimen R, Kahveci F (June 1, 2014) Hemoperfusion for Theophylline Poisoning: Case Report. Journal of Uludağ University Medical Faculty 40 2 89–93.
IEEE
[1]G. Çalışkan, N. K. Girgin, İ. Uran, B. Gül, R. İşçimen, and F. Kahveci, “Hemoperfusion for Theophylline Poisoning: Case Report”, Journal of Uludağ University Medical Faculty, vol. 40, no. 2, pp. 89–93, June 2014, [Online]. Available: https://izlik.org/JA98RB72ZA
ISNAD
Çalışkan, Gülbahar - Girgin, Nermin Kelebek - Uran, İsa - Gül, Bülent - İşçimen, Remzi - Kahveci, Ferda. “Hemoperfusion for Theophylline Poisoning: Case Report”. Journal of Uludağ University Medical Faculty 40/2 (June 1, 2014): 89-93. https://izlik.org/JA98RB72ZA.
JAMA
1.Çalışkan G, Girgin NK, Uran İ, Gül B, İşçimen R, Kahveci F. Hemoperfusion for Theophylline Poisoning: Case Report. Journal of Uludağ University Medical Faculty. 2014;40:89–93.
MLA
Çalışkan, Gülbahar, et al. “Hemoperfusion for Theophylline Poisoning: Case Report”. Journal of Uludağ University Medical Faculty, vol. 40, no. 2, June 2014, pp. 89-93, https://izlik.org/JA98RB72ZA.
Vancouver
1.Gülbahar Çalışkan, Nermin Kelebek Girgin, İsa Uran, Bülent Gül, Remzi İşçimen, Ferda Kahveci. Hemoperfusion for Theophylline Poisoning: Case Report. Journal of Uludağ University Medical Faculty [Internet]. 2014 Jun. 1;40(2):89-93. Available from: https://izlik.org/JA98RB72ZA

ISSN: 1300-414X, e-ISSN: 2645-9027

Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023